Table 2.
Cell cycle distribution of MCF7 and T47D cells treated with cytotoxic drugs and fulvestrant alone or in combination.
| Cell line | Treatment | % Sub G1 (s.d.)a | % G1 (s.d.) | % S (s.d.) | % G2/M (s.d.) |
|---|---|---|---|---|---|
| MCF7 | DMSO | 0.1 (0.1) | 60.4 (2.4) | 11.5 (0.9) | 26.0 (1.0) |
| Fulvb (50 μM) | 0.5 (0.1) | 88.5 (0.2) | 1.0 (0.3) | 9.1 (0.2) | |
| Doxb (0.75 μM) | 3.7 (0.5) | 37.2 (0.61) | 7.6 (0.4) | 50.4 (0.1) | |
| Fulv (50 μM) + Dox (0.75 μM) | 2.4 (0.1) | 40.4 (1.0) | 12.1 (1.4) | 44.2 (1.3) | |
| Fulv (10 μM) | 1.1 (0.4) | 88.3 (0.9) | 0.9 (0.2) | 8.8 (0.3) | |
| Taxb (5 nM) | 39.5 (1.0) | 21.9 (0.4) | 15.0 (0.4) | 18.5 (2.0) | |
| Ful (10 μM) + Tax (5 nM) | 26.8 (4.0) | 18.3 (1.2) | 15.0 (1.3) | 37.2 (4.3) | |
| Fulv (5 μM) | 1.1 (0.2) | 87.3 (1.0) | 0.7 (0.1) | 9.8 (0.9) | |
| VP16b (5 μM) | 2.4 (0.5) | 27.7 (0.6) | 9.4 (0.8) | 58.8 (0.1) | |
| Fulv (5 μM) + VP16 (5 μM) | 10.5 (3.9) | 29.9 (2.0) | 8.9 (2.1) | 48.6 (3.7) | |
| T47D | DMSO | 0.7 (0.3) | 66.7 (0.9) | 8.4 (0.7) | 23.0 (0.6) |
| Fulv (50 μM) | 0.9 (0.1) | 82.4 (1.4) | 2.2 (0.5) | 13.7 (0.9) | |
| Dox (0.175 μM) | 6.1 (0.6) | 3.8 (0.4) | 47.9 (4.2) | 37.4 (3.5) | |
| Fulv (50 μM) + Dox (0.175 μM) | 1.7 (0.6) | 37.9 (0.4) | 32.4 (2.5) | 26.1 (2.0) | |
| Tax (10 nM) | 42.7 (5.3) | 16.9 (1.3) | 13.2 (1.7) | 23.7 (4.2) | |
| Ful (50 μM) + Tax (10 nM) | 15.8 (0.8) | 30.0 (1.9) | 8.5 (1.0) | 43.0 (1.8) | |
| VP16 (3.5 μM) | 11.3 (1.4) | 6.6 (0.5) | 54.9 (0.7) | 22.3 (1.4) | |
| Fulv (50 μM) + VP16 (3.5 μM) | 3.1 (0.9) | 39.2 (1.0) | 33.7 (1.8) | 21.7 (1.3) |
a
s.d.: standard deviation.
b
Fulv: fulvestrant; Dox: doxorubicin; Tax: paclitaxel; VP16: etoposide.